Dhavalkumar Patel
Chief Tech/Sci/R&D Officer at UCB
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jeffrey A. Hubbell | M | - |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA.
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | 12 years |
Deborah S. Geraghty | F | - |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | - |
Florent Gros | M | 56 |
Priothera Ltd.
Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland.
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland.
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | 4 years |
Michael Clayman | M | 72 |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA.
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | 8 years |
Deborah Geraghty | M | - |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | 6 years |
Kristen M. Lorentz | F | - |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | 12 years |
Luke O'Neill | M | 60 |
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | 8 years |
Charl van Zyl | M | 57 | 7 years | |
Matthew A. Cooper | M | - |
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | 8 years |
Jonathan Peacock | M | 66 | 3 years | |
Stephan Oehen | M | 56 |
Priothera Ltd.
Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | 4 years |
Jan Berger | M | 67 | 5 years | |
Maëlys Castella | F | 58 | 1 years | |
Iain Robert McGill | M | 51 |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | - |
Ulf Arne Wiinberg | M | 66 | 8 years | |
Pierre Gurdjian | M | 63 | 8 years | |
Brice R. Suire | M | - |
Priothera Ltd.
Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | 4 years |
Caroline Vancoillie | F | - | - | |
Susan Gasser | M | 69 | 3 years | |
Geoffrey S. Ginsburg | M | 67 |
Duke University Medical Center
| 24 years |
Laura Brass | M | - |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland.
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | 5 years |
Dame Davies | M | 73 | 10 years | |
Manus Rogan | M | 55 |
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland.
Priothera Ltd.
Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | - |
Philippe Lievre | M | - |
Priothera Ltd.
Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | 4 years |
Thomas Woiwode | M | 52 |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA.
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | - |
Oscar Buset | M | - |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | 12 years |
Patricia Allen | F | 62 |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland.
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | 4 years |
Jean-Christophe Tellier | M | 65 | 13 years | |
Robert Lechler | M | - |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | - |
William Kane | M | 80 |
Duke University Medical Center
| 21 years |
Simon Read | M | 53 | 8 years | |
Elisa Petris | M | 45 |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | 5 years |
Betsy Kassler | F | - |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | - |
Hilda Buehler | F | - |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | - |
Jean Fleurial | M | 59 | 7 years | |
Denelle Waynick | F | 57 | 4 years | |
Kirsten Lund Jurgensen | M | 65 | 5 years | |
Thomas Debeys | M | - | - | |
Abhinav Kumar | M | - | 4 years | |
Stephen Keith Rhind | M | - |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | - |
Alberto Sanchez Fueyo | M | 55 |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | - |
Dominique Baeten | M | - | - | |
Natalie Wildenradt | F | - | - | |
Stanley J. Robboy | M | 82 |
Duke University Medical Center
| 26 years |
Charles-Antoine Janssen | M | 53 | 23 years | |
Ramin Farzaneh-Far | M | 47 | 8 years | |
Kerry Black | F | - | 14 years | |
Martin Murphy | M | 55 |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | - |
Harry Welten | M | 59 |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | - |
André J. Müller | M | 80 |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | - |
Thomas Dyrberg | M | 69 |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | - |
Henry Skinner | M | 60 |
Priothera Ltd.
Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | - |
Lionel Carnot | M | 56 |
Priothera Ltd.
Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | - |
Antje Witte | F | - | - | |
Sandrine Dufour | F | 57 | 4 years | |
Iris Löw-Friedrich | M | 63 | 18 years | |
Cyril Janssen | M | 53 | 9 years | |
Alonso Ricardo | M | 46 | 14 years | |
Marten Steen | M | 49 |
Priothera Ltd.
Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | - |
Laurent Schots | M | - | - | |
Jonkheer Cédric van Rijckevorsel | M | 54 | 10 years | |
Robert M. Califf | M | 72 |
Duke University Medical Center
| 29 years |
Raf Remijsen | M | - | - | |
Nilesh Kumar | M | 47 |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | - |
Xavier Michel | M | - | 11 years | |
Emmanuel Caeymaex | M | - | 30 years | |
Peter DiRoma | M | - | 6 years | |
Douangsone Vadysirisack | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Doug Treco Treco | M | 66 | 12 years | |
Ed Mathers Mathers | M | 64 | 10 years | |
Stefan Oschmann | M | 66 | 1 years | |
Andrin Oswald | M | 52 |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | - |
Matthew Stanton | M | 51 |
The University of North Carolina at Chapel Hill
| 8 years |
Marcela A. Kirberger | F | 57 |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | 3 years |
Fiona du Monceau-de Hemptinne | F | 46 | 3 years | |
Aoife Brennan | M | 48 | 2 years | |
Alexander Cumbo | M | 53 | 2 years | |
Amy K. Jassen | M | - |
The University of North Carolina at Chapel Hill
| 5 years |
John Ellis | M | - |
The University of North Carolina at Chapel Hill
| 3 years |
Albrecht de Graeve | M | 69 | 14 years | |
Bascome Majors | M | - |
The University of North Carolina at Chapel Hill
| 5 years |
Timothy Pearson | M | 56 | 4 years | |
Daniel Vasella | M | 70 |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | 17 years |
David Lubner | M | 60 | 4 years | |
Robert A. Heft | M | 69 | 4 years | |
Raj Shah | M | 46 | 5 years | |
Fabrice Enderlin | M | - | 9 years | |
Sam A. Heischuber | M | - |
The University of North Carolina at Chapel Hill
| 3 years |
Pierre Cadena | M | - |
The University of North Carolina at Chapel Hill
| 2 years |
John Chek | M | - |
The University of North Carolina at Chapel Hill
| 3 years |
David Deterding | M | - |
The University of North Carolina at Chapel Hill
| 2 years |
Davis Berg | M | - |
The University of North Carolina at Chapel Hill
| 4 years |
Trevor Shaw Slaven | M | - |
The University of North Carolina at Chapel Hill
| 4 years |
Ronald Hou | M | - |
The University of North Carolina at Chapel Hill
| 4 years |
Adam Daland | M | - |
The University of North Carolina at Chapel Hill
| 4 years |
Alastair Michael McKeever | M | - |
The University of North Carolina at Chapel Hill
| 4 years |
Andrew MacDonald | M | - |
The University of North Carolina at Chapel Hill
| 4 years |
Vijay K. Kori | M | - |
The University of North Carolina at Chapel Hill
| 4 years |
Annalee Bloomfield | F | - |
The University of North Carolina at Chapel Hill
| 4 years |
Christopher George | M | - |
The University of North Carolina at Chapel Hill
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 47 | 47.00% |
Belgium | 28 | 28.00% |
Switzerland | 16 | 16.00% |
Ireland | 10 | 10.00% |
United Kingdom | 6 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Dhavalkumar Patel
- Personal Network